Clinical trials: Chronic Obstructive Pulmonary Disease, Unspecified
- Condition Chronic Obstructive Pulmonary Disease, Unspecified
- Funder type Industry (pharma, biotech, devices)
Pulmonary Disease, Chronic Obstructive
Comparing the Efficacy of Tiotropium + Olodaterol Fixed Dose Combination (FDC) Over Tiotropium in Improvement of Lung Hyperinflation, Exercise Capacity and Physical Activity in Japanese COPD Patients
This is a multi-centre, randomised, double-blinded, active-controlled, 2-way cross over trial to assess the effects of once daily administration of orally inhaled tiotropium + olodaterol FDC or tiotropium (both delivered by the…
- Trial name
- NCT02629965
- Testing
- tiotropium, olodaterol
- Where
- 43 sites in Japan
- Volunteers
- 184 people
- Sponsor
- Boehringer Ingelheim
Chronic Obstructive Pulmonary Disease
A Phase II Study of CM326 in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease
This study is a multi-center, randomized, double-blind, placebo-controlled Phase II clinical study to evaluate the efficacy, safety, PK characteristics, PD effects and immunogenicity of CM326 in subjects with moderate to Severe…
- Trial name
- NCT07418736
- Testing
- CM326 dose 1, CM326 dose 2
- Where
- China
- Volunteers
- 318 people
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Pulmonary Disease, Chronic Obstructive
Efficacy and Safety Study of Fluticasone Furoate (FF)/GW642444 Inhalation Powder and the Individual Components in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
The Purpose of this study is to assess the efficacy and safety of two strengths of the FF/GW642444 Inhalation Powder in subject with Chronic Obstructive Pulmonary Disease (COPD)
- Trial name
- NCT01054885
- Testing
- FF Inhalation Powder, FF/GW642444 Inhalation Powder, GW642444 Inhalation Powder
- Where
- 149 sites in United States, Argentina and 7 more
- Volunteers
- 1,226 people
- Sponsor
- GlaxoSmithKline
Pulmonary Disease, Chronic Obstructive
Pharmacokinetics and Safety Comparison of Tiotropium Inhalation Powder Administered as the Bromide Salt From Hard Polyethylene Capsule Via the HandiHaler® 2 and Spiriva® HandiHaler® in Patients With Chronic Obstructive Pulmonary Disease (COPD)
The primary objective of this trial was to establish non-inferiority of lung function response to tiotropium 10 μg, formulated as inhalation powder in the polyethylene hard capsule and delivered via the HandiHaler® 2, compared to…
- Trial name
- NCT02242266
- Testing
- Tiotropium low dose, Tiotropium medium dose, Spiriva® HandiHaler® high dose
- Volunteers
- 121 people
- Sponsor
- Boehringer Ingelheim
Chronic Obstructive Pulmonary Disease
Post Marketing Surveillance of Roflumilast in Korea
The purpose of this study is to evaluate the safety and efficacy of roflumilast in the real-use conditions with its registered indications.
- Trial name
- NCT02068456
- Testing
- Roflumilast
- Where
- South Korea
- Volunteers
- 1,837 people
- Sponsor
- AstraZeneca
Chronic Obstructive Lung Disease (COLD)
Evaluation of the Safety and Efficacy of HSK39004 Dry Powder Inhaler and HSK39004 Inhalation Suspension in Chinese Patients With Chronic Obstructive Pulmonary Disease (COPD)
To evaluate the safety and efficacy of the HSK39004 Dry Powder Inhaler and HSK39004 Inhalation Suspension compared with the placebo in the treatment of Chinese patients with COPD.
- Trial name
- NCT07140328
- Testing
- HSK39004 Dry Powder Inhaler -0.75mg BID, HSK39004 Dry Powder Inhaler -1.5mg BID, HSK39004 Inhalation Suspension -3mg BID
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Haisco Pharmaceutical Group Co., Ltd.
Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Study to Evaluate the Pharmacokinetic Characteristics, Safety, Tolerability, and Preliminary Efficacy of 9MW1911 in Patients With Chronic Obstructive Pulmonary Disease (COPD).
The study will evaluate the pharmacokinetic characteristics, safety, tolerability, and preliminary efficacy of 9MW1911 in combination with standard of care COPD maintenance therapy in patients with moderate to severe COPD.
- Trial name
- NCT06175351
- Testing
- 9MW1911
- Where
- 22 sites in China
- Volunteers
- 80 people
- Sponsor
- Mabwell (Shanghai) Bioscience Co., Ltd.
COPD
Zofin to Treat Chronic Obstructive Pulmonary Disease (COPD)
A Phase I/II Randomized, Double Blinded, Placebo Trial to Evaluate the Safety and Potential Efficacy of Intravenous Infusion (IV) of Zofin for the Treatment of Chronic Obstructive Pulmonary Disease (COPD).
- Trial name
- NCT05643729
- Testing
- Zofin
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- ZEO ScientifiX, Inc.
Chronic Obstructive Pulmonary Disease
A Study to Evaluate the Efficacy and Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease
This study will evaluate the efficacy, safety, and pharmacokinetics of astegolimab in combination with standard of care chronic obstructive pulmonary disease (COPD) maintenance therapy in patients with COPD who are former or…
- Trial name
- NCT05037929
- Testing
- Astegolimab
- Where
- 193 sites in United States, Argentina and 22 more
- Volunteers
- 1,334 people
- Sponsor
- Genentech, Inc.
Chronic Obstructive Pulmonary Disease
Efficacy and Safety of Glycopyrrolate Bromide of COPD Patients
The purpose of this study is to evaluate the efficacy and safety of CHF 5259 (glycopyrrolate bromide) for the treatment of COPD patients.
- Trial name
- Trigon (NCT02189577)
- Testing
- CHF 5259
- Where
- 29 sites in Bulgaria, Germany and 2 more
- Volunteers
- 100 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
Chronic Obstructive Pulmonary Disease
Effect of Remote Physiologic Monitoring (RPM) on Outcomes in COPD Patients
This pre/post study was a retrospective analysis of unplanned hospitalization rates in a cohort of COPD subjects started on remote physiologic monitoring (RPM) at a large, outpatient pulmonary practice.
- Trial name
- NCT05518981
- Testing
- Respiratory Remote Patient Monitor (Spire Health Tag)
- Where
- United States
- Volunteers
- 126 people
- Sponsor
- Spire, Inc.
Pulmonary Disease, Chronic Obstructive
Tiotropium (18 Mcg) Once Daily Via the HandiHaler® in Patients With Chronic Obstructive Pulmonary Disease (COPD)
The primary objective of this trial is to determine whether treatment with tiotropium (18 mcg) capsule once daily via the HandiHaler reduces the proportion of patients with COPD experiencing an exacerbation and the proportion of…
- Trial name
- NCT00274547
- Testing
- Tiotropium
- Where
- 26 sites in United States
- Volunteers
- 1,829 people
- Sponsor
- Boehringer Ingelheim
Pulmonary Disease, Chronic Obstructive
Effect of Spiriva® on Health-related Quality of Life in Chronic Obstructive Pulmonary Disease (COPD) Patients Who Stopped Smoking During Treatment.
Post marketing Surveillance to gain insights into the effects of therapy with Spiriva® (tiotropium bromide) on health-related quality of life in COPD patients who stopped smoking during treatment and to obtain safety data…
- Trial name
- NCT02172547
- Testing
- Spiriva
- Volunteers
- 10,821 people
- Sponsor
- Boehringer Ingelheim
Chronic Obstructive Pulmonary Disease
Oxis 9mcg Turbuhaler Clinical Experience Investigation
The purpose of the investigation is to confirm the ADR development and the contributing factors possibly having an impact on the safety under the post-marketing actual use of Oxis 9 mcg Turbuhaler.
- Trial name
- NCT01749462
- Where
- 41 sites in Japan
- Volunteers
- 398 people
- Sponsor
- AstraZeneca
COPD
Efficacy of AZD3199 in Chronic Obstructive Pulmonary Disease (COPD) Patients
The purpose of this study is to investigate the efficacy, safety and tolerability of 4 weeks treatment with AZD3199 in moderate to severe COPD.
- Trial name
- GLAD (NCT00929708)
- Testing
- AZD3199, formoterol
- Where
- 38 sites in Bulgaria, Canada and 3 more
- Volunteers
- 329 people
- Sponsor
- AstraZeneca
Pulmonary Disease, Chronic Obstructive
General Practice Quality Assurance Project. Chronic Obstructive Pulmonary Disease (COPD) Diagnosis and Treatment
A Cross sectional observational Quality Assurance Project in General Practice to COPD Diagnosis and Treatment
- Trial name
- NCT00319813
- Testing
- Education
- Volunteers
- 8,000 people
- Sponsor
- Boehringer Ingelheim
Chronic Obstructive Pulmonary Disease (COPD)
Long Term Safety Study of NVA237 vs QAB149 in COPD Patients
The purpose of the study is to provide long term safety data of NVA237. This study will assess the safety and tolerability of a single dose strength of NVA237.
- Trial name
- NCT01697696
- Testing
- NVA237, Long-acting beta 2-agonist (LABA)
- Where
- 61 sites in United States
- Volunteers
- 511 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Obstructive Pulmonary Disease
Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD), Characterized by an Eosinophilic Phenotype
This is a parallel, Phase 2b/Phase 3, 3-arm study to investigate the efficacy, safety, and tolerability of subcutaneous (SC) treatment with lunsekimig compared with placebo in adult participants (aged 40 to 80 years, inclusive)…
- Trial name
- THESEUS (NCT07190222)
- Testing
- Lunsekimig
- Where
- 314 sites in United States, Argentina and 24 more
- Volunteers
- 942 people
- Sponsor
- Sanofi
Chronic Obstructive Pulmonary Disease (COPD)
2-arm Parallel Group Study of Fixed Combination of CHF 5993 vs Ultibro® in COPD Patients
The aim of the present study is to evaluate the superiority of the fixed triple therapy with BDP/FF/GB at a daily dose of 400/24/50 mcg respectively with that of Ultibro® Breezhaler® (DPI), fixed combination of indacaterol 85 mcg…
- Trial name
- TRIBUTE (NCT02579850)
- Testing
- Central spirometry, COPD assessment test, Local laboratory Assessments
- Where
- Italy
- Volunteers
- 1,532 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
COPD
Aerosure and Six Minute Walk Distance in Severe COPD
To investigate whether high frequency airflow oscillation (HFAO), delivered using Aerosure, increases six minute walk distance (6MWD) and reduces exertional breathlessness in patients with severe chronic obstructive pulmonary…
- Trial name
- ACCORD (NCT02007590)
- Testing
- Aerosure 25 Hz
- Where
- United Kingdom
- Volunteers
- 42 people
- Sponsor
- Actegy Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.